Thiard News@F4F

@newsen.bsky.social

2 days ago

Long-Term Efficacy and Safety of ICOTYDE™ in Plaque Psoriasis Patients Revealed Johnson & Johnson reported promising year-long results for ICOTYDE™, a once-daily oral treatment for plaque psoriasis, confirming its effectiveness and safety.

Long-Term Efficacy and Safety of ICOTYDE™ in Plaque Psoriasis Patients Revealed #United_States #Johnson_&_Johnson #Spring_House #Plaque_Psoriasis #ICOTYDE

Thiard News@F4F

@newsen.bsky.social

5 days ago

A Colorful Spring Weekend: 'Spring House' by My Little Box Draws Over 750 Fans Over 750 fans gathered in Daikanyama for the 'Spring House' event by My Little Box, celebrating spring with exclusive beauty collaborations and experiences.

A Colorful Spring Weekend: 'Spring House' by My Little Box Draws Over 750 Fans #Japan #Spring_House #Tokyo #Shu_Uemura #My_Little_Box

サードニュース@相互フォロー100%

@new3rd.bsky.social

5 days ago

代官山で体感した春の訪れ！My Little Boxの特別イベントレポート 2023年春、代官山で開催されたMy Little Boxの体験型イベント「Spring House」の模様をお届け！ファン750名以上が集結し、特別コラボを楽しんだひとときを振り返ります。

代官山で体感した春の訪れ！My Little Boxの特別イベントレポート #東京都 #渋谷区 #My_Little_Box #shu_uemura #Spring_House

2023年春、代官山で開催されたMy Little Boxの体験型イベント「Spring House」の模様をお届け！ファン750名以上が集結し、特別コラボを楽しんだひとときを振り返ります。

Thiard News@F4F

@newsen.bsky.social

1 week ago

ICOTYDE™: A Breakthrough Oral Treatment Approved for Plaque Psoriasis Johnson & Johnson's ICOTYDE™ has received FDA approval as a novel oral treatment for moderate-to-severe plaque psoriasis, a significant advancement for patient care.

ICOTYDE™: A Breakthrough Oral Treatment Approved for Plaque Psoriasis #United_States #Johnson_&_Johnson #Spring_House #Plaque_Psoriasis #ICOTYDE

Joceeニュース＠相互フォロー100%

@jocee201405.bsky.social

3 weeks ago

代官山で春を感じる体験型イベント「Spring House」開催決定！ 代官山で開催される「Spring House」では、My Little Boxとshu uemuraのコラボ展示や来場者全員プレゼントを体験できます。春の訪れを祝いながら楽しむ特別なイベント！

代官山で春を感じる体験型イベント「Spring House」開催決定！ #My_Little_Box #shu_uemura #Spring_House

代官山で開催される「Spring House」では、My Little Boxとshu uemuraのコラボ展示や来場者全員プレゼントを体験できます。春の訪れを祝いながら楽しむ特別なイベント！

Thiard News@F4F

@newsen.bsky.social

3 weeks ago

Johnson & Johnson's Nipocalimab Receives Fast Track Designation for SLE Treatment Nipocalimab, a novel treatment developed by Johnson & Johnson, has received Fast Track designation from the FDA for lupus therapy, addressing critical patient needs.

Johnson & Johnson's Nipocalimab Receives Fast Track Designation for SLE Treatment #United_States #Johnson_&_Johnson #Spring_House #nipocalimab #Systemic_Lupus

Thiard News@F4F

@newsen.bsky.social

1 month ago

Johnson & Johnson Pursues FDA Approval for Groundbreaking wAIHA Treatment with IMAAVY® Johnson & Johnson has submitted a new drug application to the FDA seeking to make IMAAVY® the first-ever approved treatment for warm autoimmune hemolytic anemia (wAIHA), a serious disease.

Johnson & Johnson Pursues FDA Approval for Groundbreaking wAIHA Treatment with IMAAVY® #United_States #Johnson_&_Johnson #Spring_House #IMAAVY #wAIHA

Thiard News@F4F

@newsen.bsky.social

1 month ago

Third Arc Bio Secures $52 Million to Enhance Cancer and Immune Therapies Third Arc Bio has successfully raised $52 million in a Series A funding extension, aiming to boost its oncology and immunology portfolio with groundbreaking therapies.

Third Arc Bio Secures $52 Million to Enhance Cancer and Immune Therapies #United_States #Spring_House #oncology #Immunology #Third_Arc_Bio

Thiard News@F4F

@newsen.bsky.social

2 months ago

Johnson & Johnson Reports Breakthrough Results in SLE Treatment with Nipocalimab Johnson & Johnson has announced promising Phase 2 results for nipocalimab, the first investigational FcRn blocker aimed at treating systemic lupus erythematosus.

Johnson & Johnson Reports Breakthrough Results in SLE Treatment with Nipocalimab #USA #Johnson_&_Johnson #Spring_House #nipocalimab #Systemic_Lupus_Erythematosus

Thiard News@F4F

@newsen.bsky.social

5 months ago

Johnson & Johnson Initiates First Head-to-Head Study for gMG Treatment Comparison at AANEM Johnson & Johnson has launched a pivotal study, the EPIC trial, comparing its IMAAVY™ with efgartigimod to assess treatment for generalized myasthenia gravis.

Johnson & Johnson Initiates First Head-to-Head Study for gMG Treatment Comparison at AANEM #USA #Johnson_&_Johnson #Spring_House #IMAAVY™ #gMG_Treatment

Thiard News@F4F

@newsen.bsky.social

5 months ago

New Study Reveals Unmet Needs in Psoriasis Care, Highlighting Preference for Oral Treatments A recent study highlights significant unmet needs in psoriasis treatments, with patients showing a strong preference for effective oral medications over injectables.

New Study Reveals Unmet Needs in Psoriasis Care, Highlighting Preference for Oral Treatments #USA #Johnson_&_Johnson #Spring_House #Psoriasis #Oral_Treatments

Thiard News@F4F

@newsen.bsky.social

5 months ago

Nipocalimab's Promising Impact on Sjögren's Disease: Insights from Recent Study Recent findings reveal that nipocalimab significantly reduced disease activity in patients with Sjögren's disease, showcasing its potential as a transformative therapy.

Nipocalimab's Promising Impact on Sjögren's Disease: Insights from Recent Study #United_States #Johnson_&_Johnson #Spring_House #nipocalimab #Sjögren's_Disease

Thiard News@F4F

@newsen.bsky.social

5 months ago

Long-term Results for Icotrokinra Show Promise in Clearing Psoriasis New long-term results from the Phase 3 ICONIC-TOTAL study reveal that Icotrokinra offers significant skin clearance and safety for psoriasis patients.

Long-term Results for Icotrokinra Show Promise in Clearing Psoriasis #USA #Johnson_&_Johnson #Spring_House #Psoriasis #Icotrokinra

Thiard News@F4F

@newsen.bsky.social

5 months ago

Icotrokinra: A Promising New Treatment for Ulcerative Colitis Icotrokinra demonstrates significant therapeutic benefits and safety for ulcerative colitis patients, as seen in recent clinical trials. The once-daily pill showed impressive clinical response rates and remission improvements.

Icotrokinra: A Promising New Treatment for Ulcerative Colitis #United_States #Ulcerative_Colitis #Johnson_&_Johnson #Spring_House #Icotrokinra

Thiard News@F4F

@newsen.bsky.social

5 months ago

TREMFYA®: A Breakthrough in Ulcerative Colitis Treatment with Sustained Results TREMFYA® (guselkumab) emerges as the first IL-23 inhibitor with a fully subcutaneous regimen, showing remarkable results in ulcerative colitis treatment over 48 weeks.

TREMFYA®: A Breakthrough in Ulcerative Colitis Treatment with Sustained Results #USA #Ulcerative_Colitis #TREMFYA® #Spring_House #guselkumab

Thiard News@F4F

@newsen.bsky.social

6 months ago

Icotrokinra Outshines Deucravacitinib in Head-to-Head Phase 3 Trials for Plaque Psoriasis Treatment Recent Phase 3 trials reveal Icotrokinra's effectiveness over Deucravacitinib for treating moderate-to-severe plaque psoriasis, promising a new oral peptide treatment option.

Icotrokinra Outshines Deucravacitinib in Head-to-Head Phase 3 Trials for Plaque Psoriasis Treatment #USA #Spring_House #Psoriasis #Icotrokinra #Deucravacitinib

Thiard News@F4F

@newsen.bsky.social

8 months ago

Johnson & Johnson Files for ICOTROKINRA FDA Approval, Pioneering Psoriasis Treatment for All Ages Johnson & Johnson aims to change psoriasis treatment with icotrokinra, an oral peptide that targets IL-23 receptors, offering hope for patients aged 12 and older.

Johnson & Johnson Files for ICOTROKINRA FDA Approval, Pioneering Psoriasis Treatment for All Ages #USA #Johnson_&_Johnson #Spring_House #Psoriasis #Icotrokinra

Thiard News@F4F

@newsen.bsky.social

9 months ago

IMAAVY™: A New Hope for Generalized Myasthenia Gravis Patients with Enhanced Disease Control Recent data highlights IMAAVY™'s superior disease control over existing treatments for generalized myasthenia gravis, offering hope to patients with this chronic condition.

IMAAVY™: A New Hope for Generalized Myasthenia Gravis Patients with Enhanced Disease Control #USA #Spring_House #IMAAVY™_Generalized_Myasthenia_Gravis

Thiard News@F4F

@newsen.bsky.social

10 months ago

Icotrokinra Shows Promising Results in Treating Scalp and Genital Psoriasis New findings from a Phase 3 study reveal that icotrokinra significantly improves skin conditions for patients suffering from psoriasis in hard-to-treat areas.

Icotrokinra Shows Promising Results in Treating Scalp and Genital Psoriasis #USA #Johnson_&_Johnson #Spring_House #Psoriasis #Icotrokinra

Thiard News@F4F

@newsen.bsky.social

11 months ago

FDA Approves IMAAVY™: A New Milestone for Myasthenia Gravis Treatment Johnson & Johnson's IMAAVY™ has received FDA approval, providing a significant advancement in treating generalized myasthenia gravis with lasting effects for patients.

FDA Approves IMAAVY™: A New Milestone for Myasthenia Gravis Treatment #United_States #Johnson_&_Johnson #Spring_House #Myasthenia_Gravis #IMAAVY

Thiard News@F4F

@newsen.bsky.social

11 months ago

Promising Results of Icotrokinra in Treating Adolescents with Plaque Psoriasis Johnson & Johnson's recent study shows Icotrokinra's effectiveness in treating plaque psoriasis in teenagers, achieving clear skin for 75% of participants.

Promising Results of Icotrokinra in Treating Adolescents with Plaque Psoriasis #United_States #Johnson_&_Johnson #Spring_House #Icotrokinra #Plaque_Psoriasis

Thiard News@F4F

@newsen.bsky.social

1 year ago

Nipocalimab: Pioneering Advancement in Sjögren's Disease Treatment Receives Fast Track Designation Nipocalimab, a groundbreaking treatment for Sjögren's disease, gains Fast Track designation by the FDA, paving the way for new therapeutic options.

Nipocalimab: Pioneering Advancement in Sjögren's Disease Treatment Receives Fast Track Designation #United_States #Johnson_&_Johnson #Spring_House #nipocalimab #Sjögren's_Disease

Thiard News@F4F

@newsen.bsky.social

1 year ago

Icotrokinra Proves Effective in Ulcerative Colitis Trial, Paving Way for New Treatment Approaches Johnson & Johnson's icotrokinra shows significant potential to improve clinical responses in ulcerative colitis, marking a possible shift in treatment strategies for patients.

Icotrokinra Proves Effective in Ulcerative Colitis Trial, Paving Way for New Treatment Approaches #United_States #Ulcerative_Colitis #Johnson_&_Johnson #Spring_House #Icotrokinra

Thiard News@F4F

@newsen.bsky.social

1 year ago

Icotrokinra Emerges as a Game-Changer in Plaque Psoriasis Treatment New findings on icotrokinra reveal its potential to redefine treatment for plaque psoriasis, showcasing impressive skin clearance and safety in a daily oral form.

Icotrokinra Emerges as a Game-Changer in Plaque Psoriasis Treatment #United_States #Johnson_&_Johnson #Spring_House #Icotrokinra #Plaque_Psoriasis

Thiard News@F4F

@newsen.bsky.social

1 year ago

TREMFYA® Shows Promise as a New Ulcerative Colitis Treatment with Unique Induction Options Johnson & Johnson's latest data on TREMFYA® reveals potential dual induction treatment methods for ulcerative colitis patients, enhancing therapeutic options.

TREMFYA® Shows Promise as a New Ulcerative Colitis Treatment with Unique Induction Options #USA #Ulcerative_Colitis #Spring_House #TREMFYA #guselkumab

Thiard News@F4F

@newsen.bsky.social

1 year ago

Latest Insights on Nipocalimab Reveal Potential for Treating IgG-Driven Autoantibody Diseases New findings on nipocalimab highlight its potential as a treatment for IgG-driven diseases. The research details its unique binding properties and clinical implications.

Latest Insights on Nipocalimab Reveal Potential for Treating IgG-Driven Autoantibody Diseases #United_States #Johnson_&_Johnson #Spring_House #nipocalimab #Autoantibody_Diseases

Thiard News@F4F

@newsen.bsky.social

1 year ago

Nipocalimab Phase 3 Study Results Published in The Lancet Neurology for gMG Patients The Lancet Neurology reveals pivotal Phase 3 study results of nipocalimab, highlighting its effectiveness for generalized myasthenia gravis.

Nipocalimab Phase 3 Study Results Published in The Lancet Neurology for gMG Patients #USA #Spring_House #nipocalimab #Myasthenia_Gravis #JNJ

Thiard News@F4F

@newsen.bsky.social

1 year ago

Nipocalimab Achieves Priority Review from U.S. FDA for Myasthenia Gravis Treatment Johnson & Johnson's nipocalimab has received Priority Review from the U.S. FDA, aiming to provide new treatment options for generalized myasthenia gravis, a serious condition.

Nipocalimab Achieves Priority Review from U.S. FDA for Myasthenia Gravis Treatment #United_States #Spring_House #nipocalimab #Myasthenia_Gravis #J&J

Thiard News@F4F

@newsen.bsky.social

1 year ago

Johnson & Johnson Pursues FDA Approval for TREMFYA® to Treat Children Johnson & Johnson has filed applications to FDA for TREMFYA®, aiming to treat children with moderate-to-severe psoriasis and juvenile psoriatic arthritis.

Johnson & Johnson Pursues FDA Approval for TREMFYA® to Treat Children #United_States #Johnson_&_Johnson #Spring_House #TREMFYA #pediatric_psoriasis

Thiard News@F4F

@newsen.bsky.social

1 year ago

Johnson & Johnson's TREMFYA® Seeks FDA Approval for Innovative Treatment of Ulcerative Colitis Johnson & Johnson is pursuing FDA approval for a groundbreaking subcutaneous induction regimen of TREMFYA® to treat ulcerative colitis, marking a significant advancement in treatment options.

Johnson & Johnson's TREMFYA® Seeks FDA Approval for Innovative Treatment of Ulcerative Colitis #United_States #Ulcerative_Colitis #TREMFYA® #Johnson_&_Johnson #Spring_House